

19 Cohen, D., Deniau, E., Maturana, A. et al. 2008. Are Child and Adolescent Responses to Placebo Higher in Major Depression than in Anxiety Disorders? A Systematic Review of Placebo-Controlled Trials. PLoS ONE 3(7):e2632.

Table 1. Placebo Response Rates in Double-Blind Placebo-Controlled Trials for Internalized Disorders in Children and Adolescents

Study	Q	N(age)	Duration	Drug	Definition of Responders	Placebo Responders	Drug > Placebo
			<i>Major</i>	<i>Depressive</i>	<i>Disorder</i>		
Kramer, Feiguine 1981 [67]	0.67	20 (13-18)	6 weeks	Amitryptiline	Authors-scale	6/10 (60%)	No
Preskorn et al. 1987 [68]	0.64	22 (6-12)	6 weeks	Imipramine	CGI	3/12 (25%)	No
Puig-Antich et al. 1987 [69]	0.77	53 (prepub)	5 weeks	Imipramine	KSADdep/ anhedonia ≤ 2	15/22 (68%)	No
Hugues et al. 1990 [70]	0.5	31 (6-12)	6 weeks	Imipramine	CDRS 50%	7/14 (50%)	No
Geller et al. 1990 [71]	0.6	31 (12-17)	8 weeks	Nortryptiline	CDRS <25%	4/19 (21%)	No
Geller et al. 1992 [72]	0.89	50 (6-12)	8 weeks	Nortryptiline	CDRS ≤ 20	5/24 (17%)	No
Kutcher et al. 1994 [73]	0.7	42 (15-19)	6 weeks	Desipramine	HDRS 50%	9/25 (36%)	No
Kye et al. 1996 [74]	0.77	31 (12-18)	6 weeks	Amitryptiline	HDRS 50%	11/13 (90%)	No
Emslie et al. 1997 [75]	0.97	96 (8-18)	8 weeks	Fluoxetine	CGI ≤ 2 or CDRS 30%	16/48 (33%)	Yes
Birmaher et al. 1998 [76]	0.73	27 (13-17)	10 weeks	Amitryptiline	HDRS 50%	11/14 (79%)	No
Klein et al. 1998 [77]	0.83	45 (13-18)	6 weeks	Desipramine	CGI ≤ 2	9/18 (50%)	No
Milin et al. 2000 [78]	0.97	286 (13-18)	12 weeks	Paroxetine	MADRS 50%	53/91 (58%)	No
Keller et al. 2001 [79]	0.85	275 (13-17)	8 weeks	Paroxetine	HDRS<8 or 50%	48/87 (55%)	No
Emslie et	0.89	219	8 weeks	Fluoxetine	CDRS 30%	54/101	No

al. 2002 [80]		(8-18)				(54%)	
Wagner et al. 2003 [81]	0.93	376 (6-17)	10 weeks	Sertraline	CDRS 40%	105/179 (59%)	Yes
March et al. 2004 [82]	1	439 (12-17)	12 weeks	Fluoxetine	CGI \leq 2	39/112 (35%)	Yes
Wagner et al. 2004 [83]	0.67	174 (7-17)	8 weeks	Citalopram	CDRS \leq 28	20/85 (24%)	No
Emslie et al. 2006 [84]	0.97	206 (7-17)	8 weeks	Paroxetine	CGI \leq 2	46/100 (46%)	No
Von Knorring et al. 2006 [85]	0.5	244 (13-18)	12 weeks	Citalopram	KSADdep/ Anhedonia \leq 2	47/77 (61%)	No
Wagner et al. 2006 [86]	0.67	268 (6-17)	8 weeks	Escitalopram	CGI \leq 2	69/132 (52%)	No
Emslie et al. 2007 [87]	0.8	367 (7-17)	8 weeks	Venlafaxine	CDRS 30%	99/165 (60%)	Yes
FDA: CN104-141 2007 [88]	ND	206 (12-17)	8 weeks	Nefazodone	CGI \leq 2	42/95 (44%)	No
FDA: 003-045 2007 [89]	ND	259 (7-17)	8 weeks	Mirtazapine	CGI \leq 2	42/85 (49%)	No
			Obsessive	Compulsive	Disorder		
DeVeugh et al. 1992 [90]	0.79	60 (10-17)	8 weeks	Clompiramine	CGI \leq 2	5/29 (17%)	Yes
March et al. 1998 [91]	0.86	189 (6-17)	12 weeks	Sertraline	CYBOCS 25%	35/95 (37%)	Yes
Geller et al. 2001 [92]	0.92	103 (6-17)	13 weeks	Fluoxetine	CYBOCS 40%	8/32 (25%)	Yes
Riddle et al. 2001 [93]	0.86	120 (8-17)	10 weeks	Fluvoxamine	CYBOCS 25%	17/63 (27%)	No
Liebowitz et al. 2002 [94]	0.72	43 (8-17)	8 weeks	Fluoxetine	CGI \leq 2	7/22 (32%)	No
Geller et al. 2004	0.96	207 (7-17)	10 weeks	Paroxetine	CYBOCS 25%	42/102 (41%)	Yes

[95]							
POTS 2004 [96]	1	112 (7-17)	12 weeks	Sertraline	CYBOCS <10	1/28 (4%)	Yes
		Non-	Obsessive-	Compulsive	Anxiety	Disorder	
Gittleman- Klein 1973 [97]	0.86	35 (6-15)	6 weeks	Imipramine	School attendance	9/19 (47%)	No
Berney et al. 1981 [98]	0.73	46 (9-15)	12 weeks	Clomipramine	CGI \leq 2	10/19 (53%)	No
Klein et al. 1992 [99]	0.7	20 (6-15)	6 weeks	Imipramine	Global improvement	4/9 (44%)	No
Simeon et al. 1992 [100]	0.43	30 (M=11.8)	4 weeks	Alprazolam	CGI \leq 2	5/13 (38%)	No
Rynn et al. 2001 [101]	0.93	22 (5-17)	9 weeks	Sertraline	CGI \leq 2	1/11 (9%)	Yes
RUPP 2001 [102]	0.82	128 (6-17)	8 weeks	Fluvoxamine	CGI \leq 2	19/65 (29%)	Yes
Birmaher et al. 2003 [103]	0.89	74 (7-17)	12 weeks	Fluoxetine	CGI \leq 2	13/37 (35%)	Yes
Wagner et al. 2004 [104]	0.95	322 (8-17)	16 weeks	Paroxetine	CGI \leq 2	59/154 (38%)	Yes
Rynn et al. 2007 [105]	0.82	323 (6-17)	8 weeks	Venlafaxine	CGI \leq 2	77/159 (48%)	Yes
March et al. 2007 [106]	0.95	293 (8-17)	16 weeks	Venlafaxine	CGI \leq 2	54/148 (37%)	Yes